Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions

Healthy

Interventions

DRUG

Placebo

Placebo; formulated as solution for inhalation without active substance.

DRUG

PRS-220

PRS-220; formulated as solution for inhalation.

Trial Locations (1)

Nucleus Network Pty Ltd., Melbourne

All Listed Sponsors

lead

Pieris Australia Pty Ltd

INDUSTRY